Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 15/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24746100 | 1.00 | TYK2 (0.45) | TYK2CDK4CCND1MAP4K1LRRK2 | |
| SCHEMBL24747223 | 0.94 | TYK2 (0.46) | TYK2CDK4CCND1MAP4K1LRRK2 | |
| SCHEMBL30316297 | 0.94 | TYK2 (0.46) | TYK2CDK4CCND1MAP4K1LRRK2 | |
| SCHEMBL30316576 | 0.90 | CDK4 (0.44) | TYK2CDK4CCND1MAP4K1LRRK2 | |
| SCHEMBL24747211 | 0.90 | CDK4 (0.44) | TYK2CDK4CCND1MAP4K1LRRK2 | |
| SCHEMBL24747219 | 0.86 | TYK2 (0.44) | TYK2CDK4CCND1MAP4K1LRRK2 | |
| SCHEMBL30316229 | 0.86 | TYK2 (0.44) | TYK2CDK4CCND1MAP4K1LRRK2 | |
| SCHEMBL24745826 | 0.85 | TYK2 (0.47) | TYK2CDK4CCND1MAP4K1LRRK2 | |
| SCHEMBL29891142 | 0.85 | TYK2 (0.47) | TYK2CDK4CCND1MAP4K1LRRK2 | |
| SCHEMBL24745891 | 0.85 | TYK2 (0.46) | TYK2CDK4CCND1MAP4K1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291235-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117120090-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | TYK2 958/4885CDK4 1753/4885CCND1 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.